Emerson Poynter LLP

Emerson Poynter announces that a class action has been commenced on behalf of an institutional investor in the United States District Court for the Northern District of California on behalf of purchasers of Connetics Corporation ("Connetics") (NASDAQ:CNCT - News) common stock during the period between June 28, 2004 and May 3, 2006 (the "Class Period").  The complaint charges Connetics and certain of its officers and directors with violations of the Securities Exchange Act of 1934. Connetics is a specialty pharmaceutical company that engages in the development and commercialization of products for the medical dermatology market.

The complaint alleges that during the Class Period, defendants made false statements about the Company's most important new drug (Velac) concerning findings that would likely prevent FDA approval. Defendants also reported false financial results by failing to properly reserve for rebates. On May 3, 2006, Connetics announced it could not file its quarterly report on time due to a restatement of its financial results. As a result of defendants' false statements, Connetics' stock traded at inflated levels during the Class Period, which allowed defendants to reap millions of dollars in insider trading proceeds. However, after the May 3, 2006 announcement, the Company's shares collapsed 45% from their high. The stock now trades at $10-$11 per share, some 63% below the Class Period high of $29.92.

According to the complaint, the true facts, which were known by the defendants but concealed from the investing public during the Class Period, were as follows: (a) the carcinogenicity study of Velac had indicated that 89 out of 160 mice treated with Velac developed tumors; (b) prior to the Class Period, Connetics had been informed by a panel of toxicology experts that they were unaware of any drug with similar results to Velac ever being approved by the FDA; (c) the Company's new Velac drug would be deemed unsafe by the FDA and would not provide the revenue and income promised by the Company; (d) the Company would not be able to achieve the operating results for 2006-2007 as projected due to its inability to launch Velac; and (e) the Company was falsifying its financials for at least 2005 and likely earlier due to improper accounting for rebates.

Register your Securities Complaint

If you have suffered from financial losses, you may qualify for damages or remedies that may be awarded in a possible class action lawsuit. Please click here and fill out the form and we will have a lawyer review your securities complaint.

By submitting this form, you are asking our lawyers to contact you. You are under no obligation to accept their services and you are free to choose which lawyer you want to work with. Lawyers are usually paid out of the proceeds of the settlement or verdict rendered.

At Emerson Poynter, it is our goal to keep you informed about important legal cases and settlements. We are dedicated to helping you resolve your legal complaints.